Compositions for preventing or treating obesity or non-alcoholic fatty liver disease comprising mitochondria-specific peptides
A mitochondria-specific peptide targets and restores damaged mitochondria, addressing the inadequacies in current treatments for obesity and NAFLD by reducing fat accumulation and inflammatory responses, providing a promising therapeutic approach for these conditions.
Patent Information
- Application Number
- PCT/KR2024/007752
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2024-06-05
- Publication Date
- 2024-12-12
AI Technical Summary
Current treatments for obesity and non-alcoholic fatty liver disease (NAFLD) are inadequate, with no approved therapies available, and existing pharmaceutical attempts have failed to effectively address the conditions.
A mitochondria-specific peptide or its dimer, capable of intracellular delivery, is used to target damaged mitochondria, restore mitochondrial function, and inhibit inflammatory responses, thereby treating or preventing obesity and NAFLD by binding to cardiolipin and maintaining membrane stability.
The peptide effectively reduces fat accumulation, improves mitochondrial membrane potential, suppresses inflammatory cytokine expression, and promotes weight loss, offering a therapeutic solution for obesity and NAFLD by targeting and restoring damaged mitochondria.
Smart Images

Figure KR2024007752_12122024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating obesity or non-alcoholic fatty liver disease comprising a mitochondrial-specific peptide
[0001] This application claims priority to Korean Patent Application No. 10-2023-0072488, filed June 5, 2023, the disclosure of which is incorporated herein by reference in its entirety.
[0002] Sequence list
[0003] This application includes a sequence listing, which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. A copy of the sequence listing, dated June 4, 2024, is named KC23078-SEQ.xml and is 32.1 kilobytes in size.
[0004] The present invention relates to a composition comprising a mitochondrial-specific peptide or a dimer thereof having both cell penetrating ability and strong mitochondrial targeting ability, for use in the prevention or treatment of obesity or non-alcoholic fatty liver disease.
[0005] Obesity refers to a state in which excessive fat tissue accumulates in the body to the point of causing health problems. In modern times, the number of obese people is rapidly increasing due to factors such as decreased overall physical activity and increased energy intake. Obesity not only causes psychological problems such as lack of confidence, but also contributes to almost all metabolic and geriatric diseases, including heart disease, high blood pressure, diabetes, and cancer. In particular, recent reports have linked obesity to non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease in which excessive fat accumulates in the liver, regardless of alcohol consumption. It is used broadly to include non-alcoholic steatohepatitis (NASH), which is accompanied by hepatocyte necrosis, inflammation, and fibrosis, as well as more advanced forms of liver cirrhosis. NAFLD is known to account for the majority of chronic liver diseases, excluding those with clear causes such as viruses or alcohol, and if it worsens, it can even lead to liver cancer. NAFLD is now considered a form of metabolic syndrome, which includes obesity, hypertension, type 2 diabetes, and dyslipidemia, all of which are caused by insulin resistance. Its prevalence is rapidly increasing in many countries, along with the increase in the obese and diabetic population. In the United States, due to the increase in obesity, it is estimated that approximately 25% of adults have NAFLD, and approximately 20% of these develop NASH (according to data from the American Liver Foundation). However, in obese adults, the incidence of NAFLD exceeds approximately 90%, and the incidence of NASH exceeds approximately 50%, representing a prevalence rate ten times that of normal adults.
[0006] Attempts by global pharmaceutical giants such as AstraZeneca and Gilead Sciences to enter the NASH treatment market have failed one after another. Intercept Pharmaceuticals' Ocaliva (active ingredient: obeticholic acid), which received FDA approval for cholangitis in 2016, also attempted to gain FDA approval as a NASH treatment in 2020, but failed. While NASH is a common liver disease worldwide, there are still no approved treatments, domestically or internationally.
[0007] [Prior Art Literature]
[0008] [Patent Document]
[0009] (Patent Document 1) International Publication No. WO2023063759A1
[0010] [Non-patent literature]
[0011] (Non-patent literature 1) Kim Jeong-hwan. "Non-alcoholic fatty liver disease." Korean Journal of Family Practice 4.2 (2014): 109-115.
[0012] (Non-patent Document 2) Oseini, Abdul M., and Arun J. Sanyal. “Therapies in non-alcoholic steatohepatitis (NASH).” Liver International37 (2017): 97-103.
[0013] The purpose of the present invention is to solve all of the above-described problems.
[0014] The present invention aims to provide a mitochondrial-specific peptide or a dimer thereof capable of intracellular delivery for the prevention or treatment of obesity or non-alcoholic fatty liver disease.
[0015] Another object of the present invention is to provide a use for preventing or treating obesity or non-alcoholic fatty liver disease, comprising an intracellularly transmissible mitochondrial-specific peptide or a dimer thereof as an active ingredient.
[0016] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver disease, comprising an intracellularly transmissible mitochondrial-specific peptide or a dimer thereof as an active ingredient.
[0017] Another object of the present invention is to provide a method for preventing or treating obesity or non-alcoholic fatty liver disease, comprising administering to a subject an intracellularly transmissible mitochondrial-specific peptide or a dimer thereof.
[0018] The purpose of the present invention is not limited to the purposes mentioned above. The purpose of the present invention will become clearer from the following description and may be realized by the means and combinations thereof set forth in the claims.
[0019] A representative configuration of the present invention to achieve the above purpose is as follows.
[0020] According to one aspect of the present invention, a pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver disease is provided, which comprises as an active ingredient a peptide or a dimer thereof comprising a unit represented by the following formula 1:
[0021] <Formula 1>
[0022] X1X2X3X4X5X6X7X8X9X 10
[0023] In the above formula 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, and X3, X6, X7 and X 10are each independently a hydrophilic amino acid, X2 and X9 are each independently an amino acid that forms a bond so that each unit can be linked to each other at least at one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
[0024] In some embodiments, nonalcoholic fatty liver disease may be selected from the group consisting of hyperlipidemia, simple hepatic steatosis, metabolic liver disease, obesity-related fatty liver disease, diabetic fatty liver disease, liver fibrosis, liver failure, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
[0025] In one embodiment, the peptide or dimer thereof may be a pharmaceutical composition exhibiting at least one of the following characteristics: (i) inhibition of mitochondrial reactive oxygen species (ROS) production, (ii) restoration of mitochondrial membrane potential, (iii) weight loss, (iv) weight loss or morphological changes in metabolically related tissues, (v) improvement of NASH indicators, (vi) inhibition of differentiation into inflammatory macrophages, and (vii) inhibition of expression or reduction in activity of inflammatory cytokines.
[0026] In another embodiment, the weight loss or morphological change in a metabolically related tissue may comprise a weight loss or restoration to normal tissue morphology in at least one tissue selected from the group consisting of liver, visceral fat, subcutaneous fat, and brown fat.
[0027] In another embodiment, the NASH indicator may include cells with advanced steatosis or ballooning or inflammatory lesions.
[0028] In another embodiment, the inflammatory macrophages may express an M1 macrophage marker selected from the group consisting of F4 / 80, CD86, MHCⅡ and CD38.
[0029] In another embodiment, the inflammatory cytokine may be selected from the group consisting of IL-6, TNF-α, IL-10 and IL-1β.
[0030] In one embodiment, X1, X4, X5 and X8 of formula 1 can each independently be leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y), valine (V), norvaline (norV), tryptophan (W), pentylglycine (pg), neopentylglycine (Npg), alanine (A) or cyclohexylalanine (Cha).
[0031] In another embodiment, X1, X4, X5 and X8 of formula 1 can each independently be leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y) or cyclohexylalanine (Cha).
[0032] In another embodiment, one or more of X1, X4, X5 and X8 of formula 1 can each independently be cyclohexylalanine (Cha).
[0033] In one implementation, X3, X6, X7 and X of formula 1 10 may each independently be arginine (R), lysine (K), homoarginine (hR), norarginine (norR), histidine (H), ornithine (O), diaminobutanoic acid (Dab), or diaminopropanoic acid (Dap).
[0034] In another implementation, X3, X6, X7 and X of formula 1 10 can each independently be arginine (R), lysine (K), homoarginine (hR), norarginine (norR), or histidine (H).
[0035] In one embodiment, X2 and X9 of formula 1 are each independently cysteine (C), homocysteine (Hcy), penicillamine (Pen), selenocysteine (U), or leucine (L), provided that X2 and X9 may not both be leucine (L).
[0036] In one embodiment, the dimer disclosed in the present invention may be one in which the peptides represented by Formula 1 are linked in an anti-parallel direction to each other.
[0037] In another embodiment, the peptide represented by Formula 1 may be a peptide consisting of any one of the amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 19.
[0038] In another embodiment, the peptide or dimer thereof disclosed in the present invention may have the activity of binding to mitochondria.
[0039] According to another aspect of the present invention, a food composition for controlling obesity or non-alcoholic fatty liver disease is provided, comprising the peptide or a dimer thereof disclosed in the present invention as an active ingredient.
[0040] According to another aspect of the present invention, a method for preventing or treating obesity or non-alcoholic fatty liver disease is provided, comprising administering a peptide or a dimer thereof disclosed in the present invention to a subject in need thereof.
[0041] According to another aspect of the present invention, a method for reducing body weight or suppressing weight gain in a subject is provided, comprising administering to a subject in need thereof a peptide or a dimer thereof disclosed in the present invention.
[0042] The mitochondrial-specific peptide or its dimer disclosed in the present invention exhibits excellent cell penetration through its double-sided α-helical structure, and the α-helix can be removed within the cell, thereby reducing the toxicity of the peptide. In addition, it has the effect of preserving / restoring the structure of the cristae by specifically binding to the exposed cardiolipin of damaged mitochondria, thereby restoring mitochondrial dysfunction. In particular, the peptide of the present invention can maintain the stability of the mitochondrial inner membrane in adipocytes with underexpression of cardiolipin synthase and mitochondrial dysfunction, and suppresses the production of the inflammasome, an inflammation-regulating complex, thereby suppressing inflammation-related mechanisms (e.g., expression of inflammatory cytokines, differentiation of inflammatory macrophages, etc.). Through this, the mitochondrial-specific peptide disclosed in the present invention can help treat or prevent obesity or non-alcoholic fatty liver disease (e.g., NAFLD, NASH, etc.).
[0043] Figure 1 is a schematic diagram showing the mechanism of promoting inflammatory response by inflammasome (inflammation regulatory complex) composed of damaged factors in mitochondria in hepatocytes.
[0044] Figures 2a and 2b are graphs showing the inhibitory effect of CMP3013 (10, 30, or 100 nM) on ROS production (Figure 2a) and mitochondrial membrane potential preservation (Figure 2b) in damaged hepatocytes (HepG2). Hepatocyte damage was induced by treatment with hydrogen peroxide (H2O2), mimicking the conditions of mitochondrial dysfunction caused by non-alcoholic fatty liver disease.
[0045] Figures 3a to 3d are diagrams showing the inhibitory effect of CMP3013 on lipid accumulation in hepatocytes (HepG2). Figure 3a is an optical micrograph showing accumulated lipid stained using an Oil Red O stain kit after treating hepatocytes with oleic acid (500 μM) and different concentrations of CMP3013 (10, 30, or 100 nM) for 24 hours. Figures 3b and 3c are graphs showing the remaining lipid content confirmed by measuring the absorbance (OD500 nm) after dissolving the accumulated lipid by treating it with 100% isopropanol. Figure 3b shows that the lipid accumulation inhibitory effect is dependent on the concentration of CMP3013, and Figure 3c shows that it is dependent on the treatment time of CMP3013 (24 hours or 48 hours). Figure 3d shows the results of a cytotoxicity test (WST-1) of oleic acid on HepG2 cells.
[0046] Figure 4a is a diagram showing the lipolysis promotion mechanism of Exendin-4 (Ex-4). Figure 4b is a graph showing the results comparing the lipid accumulation inhibitory effects of CMP3013 (10, 30, or 100 nM) and Exendin-4 (200 nM) in HepG2 cells.
[0047] Figure 5 is a schematic diagram illustrating the administration schedule (intraperitoneal injection) of a high-fat diet and CMP3013 to create an obese mouse model. The control group was administered saline (vehicle) instead of CMP3013.
[0048] Figures 6a to 6e show the results of confirming the status (body weight, feed intake, etc.) of the control group and the CMP3013 administration group induced by high-fat diet. Figure 6a is a photograph of the control group and the CMP3013 administration group in the 9th week of high-fat diet. Figures 6b to 6d show the body weight (Figure 6b), body weight change (Figure 6c left panel), final body weight change (Figure 6c right panel), and feed intake (Figure 6d) of the mouse model measured at one-week intervals from the time of CMP3013 administration. The body weight change was calculated by the formula ((final measured weight - initial weight) / initial weight)*100(%). Figure 6e is a graph comparing the blood glucose (mg / dL) levels of the control group and the CMP3013 administration group in the 9th week of high-fat diet. The blood glucose level was measured after fasting for 12 hours.
[0049] Figures 7a and 7b are diagrams showing the tissue morphology (Figure 7a) and weight (Figure 7b) of the liver, visceral fat (iWAT), subcutaneous fat (eWAT), and brown fat (BAT) of the control group and CMP3013 administration group sacrificed at the 9th week of a high-fat diet.
[0050] Figure 8 shows microscopic photographs of the livers of the control and CMP3013-administered groups sacrificed at the 9th week of a high-fat diet, stained with H&E. The microscopic photographs were taken at a magnification of 100x and were obtained from a total of four animals.
[0051] Figures 9a to 9d are graphs showing the proportion of cells that had ballooned in the hepatocytes of the control group and the CMP3013 administration group (Figure 9a), the grade of ballooned hepatocytes (Figure 9b), and the grade of steatosis (Figure 9c), and a microscopic photograph confirming the inflammatory response of the hepatocytes (Figure 9d).
[0052] Figure 10 is a schematic diagram of the differentiation process of bone marrow cells into bone marrow-derived macrophages (BMDM) and treatment with LPS and CMP3029.
[0053] Figures 11a and 11b are graphs confirming the inhibitory effect of CMP3029 on the secretion of inflammatory cytokines in bone marrow-derived macrophages. Figure 11a shows the results confirming the concentrations of inflammatory cytokines IL-6, TNF-α, and IL-10 in the untreated group (NT), CMP3029-treated group (NT+3029 1 μM), LPS-treated group (LPS), and LPS and CMP3029-treated group (LPS+3029 500 nM or LPS+3029 1 μM), and Figure 11b shows the results confirming the concentrations of inflammasome indicator IL-1β in the control group (LPS+Nig) and CMP3029-treated group (LPS+Nig+3029 (1 μM)). For IL-1β, secondary stimulation was applied by treating with nigericin (Nig, 10 μM) for 30 minutes, and then measurement was performed.
[0054] Figures 12a to 12d are graphs showing the increase in expression of M1 markers F4 / 80 (Figure 12a), CD86 (Figure 12b), MHCⅡ (Figure 12c), and CD38 (Figure 12d) and the inhibitory effect of CMP3029 on differentiation into M1 after LPS treatment of bone marrow-derived macrophages, as confirmed through flow cytometry.
[0055] Figure 13 is a graph showing the cytotoxicity test of CMP3029 (0, 100, 500, or 1000 nM) against bone marrow-derived macrophages.
[0056] The detailed description of the present invention described below will be described with reference to specific drawings (if any) regarding specific embodiments in which the present invention may be practiced; however, the present invention is not limited thereto, but is defined only by the appended claims to the full scope equivalent to or equivalent to what the claims describe. It should be understood that the various embodiments / embodiments of the present invention, while different from each other, are not necessarily mutually exclusive. For example, specific shapes, structures, and characteristics described herein may be changed from one embodiment / embodiment to another, or multiple embodiments / embodiments may be combined, without departing from the spirit and scope of the present invention. Technical and scientific terms used herein, unless otherwise defined, have the same meaning as commonly used in the art to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and terms expressed in the singular should be construed to also refer to the plural (i.e., at least one), unless the context makes it inappropriate.
[0057] definition
[0058] The term "unit" or "peptide unit" as used herein means the smallest unit constituting a monomeric peptide or dimeric peptide, wherein the unit is composed of 10 amino acids. The unit constitutes part or all of the monomeric peptide.
[0059] The term "peptide" refers to an amino acid polymer that may include as components not only natural amino acids but also unnatural amino acids (e.g., isomers such as β-amino acids and D-amino acids). For example, when one of the hydrophobic amino acids constituting the peptide is defined as leucine (L), the term "leucine (L)" is used to mean not only L-leucine in the form of the natural α-amino acid, but also its positional isomer β-leucine and its mirror image isomer D-leucine. Other amino acids described herein (e.g., isoleucine (I), phenylalanine (F), tyrosine (Y), valine (V), tryptophan (W), arginine (R), lysine (K), histidine (H), etc.) are also used to mean including their isomers in the same manner as above.
[0060] The term "treatment" generally refers to obtaining a desired pharmacological and / or physiological effect. Such effect is therapeutic in that it partially or completely cures a disease and / or the adverse effects caused by the disease. Desirable therapeutic effects include, but are not limited to, preventing the occurrence or recurrence of a disease, improving symptoms, reducing any direct or indirect pathological consequences of the disease, slowing the progression of the disease, improving or alleviating the disease state, and improving or improving the prognosis. Preferably, "treatment" may refer to medical intervention for an existing disease or disorder.
[0061] The term "prevention" means obtaining a desired preventive pharmacological and / or physiological effect with a view to partially or completely preventing a disease or its symptoms.
[0062] The term "administration" means providing a substance (e.g., a peptide comprising a unit represented by Formula 1 of the present invention or a dimer thereof, or a composition comprising one or more of these as an active ingredient) to a subject for achieving a preventive or therapeutic purpose (e.g., preventing or treating obesity or non-alcoholic fatty liver disease).
[0063] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound, composition, or drug sufficient to treat a specified disease, condition, or disorder, such as by improving a specified function, e.g., enhancing or increasing a desired and / or beneficial function, reducing or diminishing an undesirable function, or ameliorating, palliating, attenuating, and / or delaying one or more of its symptoms. For example, in the context of obesity or non-alcoholic fatty liver disease, an effective amount includes an amount sufficient to delay or reverse indices associated with fat accumulation or non-alcoholic fatty liver disease.
[0064] The term "subject" is used interchangeably with "subject" or "patient" and may be a mammal, such as a primate (e.g., human), a companion animal (e.g., dog, cat, etc.), a livestock animal (e.g., cow, pig, horse, sheep, goat, etc.), and a laboratory animal (e.g., rat, mouse, guinea pig, etc.), in need of prevention or treatment of obesity or non-alcoholic fatty liver disease. Preferably, the subject is a human.
[0065] The term "about" as used herein refers to the typical error range for each value known to those of ordinary skill in the art. Furthermore, unless otherwise specified, all numbers, values, and / or expressions expressing ingredients, conditions, compositions, amounts, and so forth used herein should be understood as being modified by the term "about" because such numbers are approximations that inherently reflect various uncertainties of measurement in obtaining such values, among other things.
[0066] Use of mitochondrial-specific peptides for the prevention or treatment of obesity or fatty liver disease
[0067] The present invention is based, at least in part, on the surprising discovery that administration of a mitochondrial-specific peptide or a dimer thereof disclosed herein has a significant effect in inhibiting fat accumulation or improving fatty liver-related markers in subjects suffering from obesity or non-alcoholic fatty liver disease.
[0068] According to one aspect of the present invention, a use of a peptide or a dimer thereof comprising a unit represented by the following formula 1 for preventing or treating obesity or fatty liver is provided:
[0069] <Formula 1>
[0070] X1X2X3X4X5X6X7X8X9X 10
[0071] In the above formula 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, and X3, X6, X7 and X 10 are each independently a hydrophilic amino acid, X2 and X9 are each independently an amino acid that forms a bond so that each unit can be linked to each other at least at one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
[0072] The mitochondrial-specific peptide or dimer thereof disclosed in the present invention interacts with cardiolipin exposed to a damaged mitochondrial outer membrane, thereby preserving / restoring the structure of cristae and thus restoring mitochondrial dysfunction.
[0073] Mitochondrial-specific peptides or dimers thereof can be provided for the prevention or treatment of obesity or non-alcoholic fatty liver disease by specifically binding to mitochondria, specifically damaged or exposed cardiolipin, present in damaged hepatocytes or macrophages and improving mitochondrial function.
[0074] Typically, adipocytes underexpress cardiolipin synthase, which reduces the production of cardiolipin, a key phospholipid that supports the mitochondrial inner membrane, which can lead to cardiolipin oxidation and inner membrane damage. When mitochondria are damaged, the resulting loss of inner membrane stability prevents many protein complexes from functioning, leading to the release of products produced within mitochondrial organelles (e.g., damaged mtDNA, ROS, damaged cardiolipin, ATP, etc.) into the cytoplasm. These mitochondrial products then interact with activated and expressed proteins in the nucleus (e.g., Nlrp3, Il1b, etc.) to form the inflammasome (see Figure 1). The formation of the inflammasome activates inflammatory pathways, leading to increased expression of inflammatory cytokines, and can lead to the progression of NAFLD to NASH.
[0075] The mitochondrial-specific peptide disclosed in the present invention has been demonstrated to bind to (damaged) cardiolipin within mitochondria, maintain the stability of the inner membrane, and restore the structure of cristae, thereby normalizing damaged mitochondria. Furthermore, the peptide of the present invention inhibits the formation of inflammasomes by binding to cardiolipin secreted from damaged mitochondria and blocking the inflammatory response. In other words, by restoring the structure of mitochondria or inhibiting the inflammatory response pathway, it exhibits effects such as suppressing ROS production, increasing ATP production, restoring membrane potential, suppressing the expression of inflammatory cytokines, suppressing the expression of inflammatory macrophages (M1), and inhibiting fat accumulation, which may be helpful in the treatment or prevention of obesity or non-alcoholic fatty liver disease.
[0076] The term "obesity" refers to a phenomenon in which body weight increases abnormally due to the accumulation of fat molecules in fat cells when the calories metabolized are less than the calories consumed, and is the cause of most metabolic / age-related diseases (e.g., heart disease, high blood pressure, diabetes, kidney disease, depression, cancer, etc.).
[0077] The term "fatty liver" refers to a condition in which fat (e.g., neutral fat) is abnormally accumulated in the liver, typically accounting for more than 5% of the liver's weight. Depending on the cause, it can be divided into alcoholic fatty liver disease and non-alcoholic fatty liver disease. If worsened, it can progress to steatohepatitis accompanied by inflammation, and if further deteriorated, it can progress to cirrhosis or liver cancer. Preferably, the fatty liver disease of the present invention is non-alcoholic fatty liver disease.
[0078] In one embodiment, the peptide or dimer thereof of the present invention may be useful for preventing or treating obesity.
[0079] In one embodiment, the peptide or dimer thereof of the present invention may be useful for reducing body weight or inhibiting weight gain.
[0080] In one embodiment, the peptide of the present invention or a dimer thereof may be useful for preventing or treating non-alcoholic fatty liver disease.
[0081] In one embodiment, the peptide or dimer thereof of the present invention may be useful for delaying or preventing the progression of non-alcoholic fatty liver disease.
[0082] In one embodiment, nonalcoholic fatty liver disease may be selected from the group consisting of hyperlipidemia, simple hepatic steatosis, metabolic liver disease, obesity-related fatty liver disease, diabetic fatty liver disease, liver fibrosis, liver failure, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer, but may include, without limitation, cases in which cardiolipin in mitochondria is damaged due to fatty liver. Preferably, nonalcoholic fatty liver disease may be nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
[0083] In another embodiment, the mitochondrial-specific peptide or dimer thereof disclosed in the present invention may exhibit a preventive or therapeutic effect on obesity or non-alcoholic fatty liver disease through at least one of the following effects: (i) inhibition of mitochondrial ROS (reactive oxygen species) production, (ii) restoration of mitochondrial membrane potential, (iii) weight reduction, (iv) weight reduction or morphological change of metabolic tissues, (v) improvement of NASH indicators, (vi) inhibition of differentiation into inflammatory macrophages, and (vii) inhibition of expression or reduction of activity of inflammatory cytokines.
[0084] In another embodiment, the weight loss or morphological change in a metabolically related tissue may comprise a weight loss or restoration to normal tissue morphology in at least one tissue selected from the group consisting of liver, visceral fat, subcutaneous fat, and brown fat.
[0085] In another embodiment, NASH indicators may include cells with advanced steatosis or ballooning, or inflammatory lesions. In one embodiment, administration of the mitochondrial-specific peptide of the present invention to mice induced with obesity through a high-fat diet (HFD) resulted in a significant reduction in the grade of steatosis, as well as a reduction in the number of ballooning cells and the grade of ballooning hepatocytes. In addition, inflammatory response factors identified through microscopy were also reduced and improved by administration of the mitochondrial-specific peptide of the present invention (see Example 3).
[0086] In another embodiment, the inflammatory macrophages may express an M1 macrophage marker selected from the group consisting of F4 / 80, CD86, MHCⅡ, and CD38. The mitochondrial-specific peptide of the present invention can inhibit differentiation into inflammatory macrophages.
[0087] In another embodiment, the inflammatory cytokine may be selected from the group consisting of IL-6, TNF-α, IL-10, and IL-1β. The mitochondrial-specific peptide of the present invention may inhibit the expression of inflammatory cytokines, thereby blocking inflammatory pathways and inhibiting the progression of NASH.
[0088] The mitochondrial-specific peptide of the present invention (e.g., CMP3013, CMP3029, etc.) exhibits an effect of inhibiting fat accumulation and an effect of inhibiting inflammatory response in hepatocytes or macrophages.
[0089] In one embodiment, the effects of the mitochondrial-specific peptide (e.g., CMP3013) of the present invention on inhibiting ROS production, restoring mitochondrial membrane potential, and inhibiting fat accumulation were confirmed in human hepatocytes treated with hydrogen peroxide to mimic conditions of mitochondrial dysfunction due to non-alcoholic fatty liver disease (see Example 2, etc.).
[0090] In one embodiment, administration of the mitochondrial-specific peptide of the present invention (e.g., CMP3013) to mice induced to become obese through a high-fat diet (HFD) resulted in a weight loss effect, and showed an effect of improving the morphology of tissues related to metabolism (e.g., liver, etc.) and reducing their weight (see Example 3, etc.).
[0091] In one embodiment, improvement in indicators associated with NASH (e.g., steatosis, ballooning cellular lesions, inflammation, etc.) was observed (see Example 3, etc.).
[0092] In one embodiment, the mitochondrial-specific peptide of the present invention (e.g., CMP3029) exhibited an effect of inhibiting the secretion of inflammatory cytokines and an effect of inhibiting differentiation into inflammatory macrophages (M1) (see Example 4, etc.).
[0093] Mitochondrial-specific peptide or dimer thereof
[0094] The mitochondrial-specific peptide of the present invention has excellent cell penetration ability and mitochondrial targeting ability by arranging hydrophobic amino acids and hydrophilic amino acids at specific positions of the peptide, and without being bound by theory, it can exhibit a therapeutic effect on obesity or non-alcoholic fatty liver disease by restoring damaged mitochondria through the above cell penetration ability and mitochondrial targeting ability. The mitochondrial-specific peptide of the present invention can form a dimeric peptide by linking each unit consisting of a total of 10 amino acids through bonds with each other at one or two positions, and each unit can contain an appropriate ratio of hydrophobic amino acids and hydrophilic amino acids, for example, 1:1, specifically 4 each.
[0095] The peptide unit of the present invention can form an α-helical amphipathic (double-sided) dimeric bundle peptide, and the increased α-helical degree increases the intracellular penetration rate, and the α-helix can be removed within the cell, thereby reducing the toxicity of the peptide. Since the cell penetration ability of the dimer is more than 100 times superior to that of a single-stranded α-helical peptide, once the dimeric bundle is formed, it can be easily delivered into cells even at nanomolar concentrations. The disulfide bond of the dimeric bundle peptide delivered into cells at nanomolar concentrations can be easily reduced to monomers in the intracellular environment and target mitochondria. It has been experimentally confirmed that the peptide delivered in this way specifically binds to abnormal mitochondria, prevents further mitochondrial damage, or restores the function of damaged mitochondria (WO 2015 / 057009).
[0096] In one embodiment, each amino acid constituting the peptide is not limited in type as long as it exhibits amphipathic properties and can maintain an α-helical structure, and any hydrophobic amino acid or hydrophilic amino acid widely known in the technical field to which the present invention pertains can be appropriately selected and used.
[0097] According to another aspect of the present invention, the mitochondrial-specific peptide may be a monomeric peptide represented by the following formula 1 or a dimer thereof:
[0098] <Formula 1>
[0099] X1X2X3X4X5X6X7X8X9X 10
[0100] In formula 1, X1, X4, X5 and X8 are each independently a hydrophobic amino acid; X3, X6, X7 and X 10 are each independently a hydrophilic amino acid; X2 and X9 are each independently an amino acid that forms a bond such that each unit can be linked to each other at least at one position among X2 and X9 to form a dimeric peptide; X1 is the N-terminal and X 10 is the C-terminal.
[0101] The term "hydrophilic amino acid" can mean a polar amino acid, and encompasses amino acids that have an affinity for (can mix with) water, a polar solvent.
[0102] The term "hydrophobic amino acid" may refer to an amino acid with no or significantly low polarity, and encompasses amino acids that have no affinity for water, a polar solvent (the property of not mixing with water).
[0103] In one embodiment, the peptide of the present invention exhibits amphipathic properties and can form an α-helical structure.
[0104] In some embodiments, the reference amino acid leucine (L) in the hydrophobic moiety of the peptide (amino acids at positions X1, X4, X5 and X8 in Formula 1) was substituted with several other hydrophobic amino acids to induce stronger hydrophobic interactions between the peptide and the fatty acid side chains in the target cardiolipin.
[0105] In one embodiment, X1, X4, X5 and X8 can each independently be leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y), valine (V), norvaline (norV), tryptophan (W), pentylglycine (pg), neopentylglycine (Npg), alanine (A) or cyclohexylalanine (Cha). Specifically, X1, X4, X5 and X8 can each independently be leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y) or cyclohexylalanine (Cha). More specifically, X1, X4, X5 and X8 can each independently be leucine (L), isoleucine (I), phenylalanine (F), or cyclohexylalanine (Cha).
[0106] In one embodiment, one or more of X1, X4, X5, and X8 can each independently be cyclohexylalanine (Cha). Specifically, one, two, or three of X1, X4, X5, and X8 can each independently be cyclohexylalanine (Cha). More specifically, two or three of X1, X4, X5, and X8 can each independently be cyclohexylalanine (Cha).
[0107] In one embodiment, X3, X6, X7 and X 10 may each independently be arginine (R), lysine (K), homoarginine (hR), norarginine (norR), histidine (H), ornithine (O), diaminobutanoic acid (Dab), or diaminopropanoic acid (Dap). Specifically, X3, X6, X7, and X 10 can each independently be arginine (R), lysine (K), homoarginine (hR), norarginine (norR), or histidine (H). More specifically, X3, X6, X7, and X 10 can each independently be arginine (R), homoarginine (hR), or norarginine (norR). More specifically, X3, X6, X7, and X 10 Each can be arginine (R).
[0108] In one embodiment, X2 and X9 can each independently be cysteine (C), homocysteine (Hcy), penicillin (Pen), selenocysteine (U), or leucine (L), provided that X2 and X9 are not both leucine (L). Specifically, X2 and X9 can each independently be cysteine (C), homocysteine (Hcy), or selenocysteine (U). More specifically, X2 and X9 can each independently be cysteine (C).
[0109] The bond formed between each monomer peptide may include any type of bond that connects the peptides so as to exhibit the properties desired by the present invention, and may include, for example, a covalent bond. The covalent bond is not particularly limited as long as it is a type of covalent bond that can improve the α-helix degree without impairing the function of the peptide. For example, it may be one or more bonds selected from the group consisting of a disulfide bond between cysteines, a diselenide bond, an ester bond, a maleimide bond, a thioester bond, a thioether bond, and a bond formed by a click reaction. More specifically, the covalent bond may be at least one selected from the group consisting of a disulfide bond between cysteine (C), homocysteine (Hcy) or penicillamine (Pen), a diselenide bond between selenocysteine (U), an ester bond, a maleimide bond using a thiol functional group capable of participating in a reaction, a thioester bond, a thioether bond, and a bond by a click reaction when the unnatural amino acid comprises a triple bond or an azide group capable of inducing a click reaction.
[0110] When a disulfide bond (disulfide bond) is formed between two units forming a dipeptide, if cysteine (C) is used in the unit, there are four atoms (CSSC; C, carbon; S, sulfur) between the two unit peptide backbones. In this case, if homocysteine (Hcy) is used instead of cysteine (C), the bond distance between the two unit peptide backbones can be adjusted to five (CCSSC or CSSCC) or six (CCSSCC). In one embodiment, a dimer in which one cysteine and one homocysteine are linked by oxidation can be used. In addition, selenocysteine (U) or penicillamine (Pen) can be used instead of cysteine to form a disulfide bond of diselenide, hybridization or ester with cysteine or penicillamine.
[0111] In one embodiment, the peptide represented by formula 1 may have a compound bound to the N-terminus or C-terminus. For example, the compound may be an active ingredient that acts on cells (e.g., a therapeutic drug), a fatty acid that further enhances cell penetration ability (e.g., C6 to C bound at the position of X1 of the dimeric peptide). 16 fatty acid), or a marker compound such as a fluorescent substance. In some embodiments, the dimeric peptide may be lipidated at the N-terminus with a fatty acid. Specifically, the dimeric peptide may have a C6 to C 16 Fatty acids may be bound. This fatty acid binding may further enhance cell penetration.
[0112] In one embodiment, the dimeric peptide may be such that the peptides (monomeric peptides) comprising each monomer are all linked in a parallel direction from the N-terminus to the C-terminus, or two peptides, one of which is linked in an N-terminus to the C-terminus direction and the other in a C-terminus to the N-terminus direction, i.e., in an antiparallel direction. Preferably, the peptides (monomeric peptides) comprising each monomer may be linked in an antiparallel direction to each other. At this time, the sequences of each monomer may be the same or different from each other.
[0113] In one embodiment, the mitochondrial-specific peptide or dimer thereof of the present invention may have the activity of targeting and / or interacting (binding) with mitochondria (e.g., their outer membrane, damaged portions or cardiolipin).
[0114] In one embodiment, the mitochondrial-specific peptide of the present invention or a dimer thereof may be included in the composition in an effective amount, for example, an amount effective to maintain, restore, or improve mitochondrial function, or an amount effective to prevent the development of obesity and / or non-alcoholic fatty liver disease. The peptide of the present invention is advantageous in that it exhibits sufficient efficacy even at low concentrations, such as nanomolar. Specifically, the peptide of the present invention or a dimer thereof may be contained at a concentration of about 1 nM to about 150 nM, about 10 nM to about 150 nM, about 1 nM to about 100 nM, about 10 nM to about 100 nM, about 1 nM to about 80 nM, about 10 nM to about 80 nM, about 1 nM to about 60 nM, about 10 nM to about 60 nM, about 1 nM to about 50 nM, about 10 nM to about 50 nM, about 20 nM to about 40 nM, or about 30 nM. The effective amount of the peptide can be appropriately determined by a person skilled in the art taking into account the amount of the effective ingredient required to prevent or treat obesity or non-alcoholic fatty liver disease in a subject.
[0115] The mitochondrial-specific peptide or dimer thereof of the present invention exhibits little or no cytotoxicity at an effective concentration, and exhibits the effect of restoring various mitochondrial dysfunctions by specifically targeting mitochondria (particularly, cardiolipin present in the inner mitochondrial membrane). Specifically, the dimer peptide of the present invention was confirmed in a previous study to exhibit cytotoxicity only at concentrations above micromolar level, to be present in a remarkably high proportion of the mitochondrial fraction when treated to cells, and to be preferentially targeted to damaged mitochondria. In addition, in one embodiment of the present invention, it was confirmed that the dimer peptide at a concentration of about 1 micromolar had no effect on cultured cells (see Example 4, etc.).
[0116] In one embodiment, the monomeric peptide represented by formula 1 comprises an amino acid sequence of Hfa-Cys-Arg-Hfa-Hfa-Arg-Arg-Hfa-Cys-Arg, wherein Hfa may be a hydrophobic amino acid selected from the group consisting of leucine (L), phenylalanine (F), tyrosine (Y), and cyclohexylalanine (Cha).
[0117] In one embodiment, one or more of the Hfas can independently be cyclohexylalanine (Cha).
[0118] In another embodiment, the mitochondrial-specific peptide of the present invention may comprise or consist of any one of the amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 19 set forth in Table 1 below, but is not limited to the amino acid sequence as long as the amphipathicity and α-helical structure of the monomeric peptide can be maintained. In another embodiment, the mitochondrial-specific peptide of the present invention may be a homodimer (including a dimer of two peptides having different sequences) in which peptides composed of the monomers of formula 1 each consisting of 10 amino acids are linked to each other, but may be a heterodimer in which another monomeric peptide having a different amino acid length or a different sequence characteristic from formula 1 is linked to the monomer of formula 1, as long as the unique α-helical structure of the present invention is maintained. For example, another monomer peptide having a different length of amino acids may be a monomer peptide having one or more amino acids added to one or both ends of the monomer peptide of formula 1 to make it longer.
[0119]
[0120] In one embodiment, the monomeric and dimeric peptides of the present invention can be prepared by any suitable method known in the art. For example, the monomeric peptide can be prepared by solid-phase peptide synthesis, and the dimer can be prepared by oxidation under air conditions.
[0121] Pharmaceutical composition
[0122] According to another aspect of the present invention, a pharmaceutical composition comprising a mitochondrial-specific peptide or a dimer thereof disclosed herein as an active ingredient is provided.
[0123] In one embodiment, the peptide or dimer thereof of the present invention can be used in the manufacture of a medicament for use in the pharmaceutical applications disclosed herein.
[0124] According to one embodiment, the researchers of the present invention have confirmed that the dimeric peptide of the present invention moves into cells and targets mitochondria even at a concentration of less than 100 nM, and exhibits a restorative effect on mitochondrial dysfunction even at a concentration of nanomolar, in contrast to existing mitochondrial-specific peptides that exhibit a restorative effect on mitochondrial dysfunction at a concentration of micromolar (see Korean Patent Publication No. 10-2023-0054285). Therefore, the pharmaceutical composition can contain the peptide at a nanomolar concentration, and exhibits excellent therapeutic effects even at such a low concentration of nanomolar.
[0125] To prepare a pharmaceutical composition of the present embodiment, the peptide of the present invention or its dimer may be mixed with a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical composition may be prepared in the form of a lyophilized preparation or an aqueous solution. See, for example, Remington's Pharmaceutical Sciences and US Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984).
[0126] Pharmaceutically acceptable carriers and / or excipients (including stabilizers) are nontoxic to the subject at the dosages and concentrations employed and include, but are not limited to: buffers (e.g., phosphate, citrate, or other organic acids); antioxidants (e.g., ascorbic acid or methionine); preservatives (e.g., octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens (e.g., methyl or propyl paraben), catechol, resorcinol, cyclohesanol, 3-pentanol, and m-cresol); low molecular weight (about 10 residues or less) polypeptides; proteins (e.g., serum albumin, gelatin, or immunoglobulins); hydrophilic polymers (e.g., polyvinylpyrrolidone); amino acids (e.g., glycine, glutamine, asparagine, histidine, arginine, or lysine); monosaccharides, disaccharides, and other carbohydrates (e.g., glucose, mannose, or dextrins); chelating agents (e.g., EDTA); sugars (e.g., sucrose, mannitol, trehalose, or sorbitol); salt-forming counterions (e.g., sodium); metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants (e.g., TWEEN®, PLURONICS®, or polyethylene glycol (PEG)).
[0127] The pharmaceutical composition of the present invention may be formulated into a suitable form known in the art, depending on the route of administration. The pharmaceutical composition should generally be sterilized and stable under the conditions of manufacture and storage. The amount of active ingredient that can produce a single dosage form will vary depending on the subject to be treated and the mode of administration. The amount of active ingredient that can produce a single dosage form will generally be that amount that produces a therapeutic effect. Typically, this amount will range from about 0.01 percent to about 99 percent of the active ingredient, preferably from about 0.1 percent to about 70 percent, and most preferably from about 1 percent to about 30 percent of the active ingredient in combination with a pharmaceutically acceptable carrier / excipient.
[0128] Food composition
[0129] According to another aspect of the present invention, a food composition for controlling obesity or non-alcoholic fatty liver disease is provided, comprising a mitochondrial-specific peptide or a dimer thereof disclosed herein as an active ingredient.
[0130] The term "medical food" or "nutraceutical food" refers to a food manufactured from raw materials or ingredients that have the potential to have a beneficial function for the human body, and that maintains or improves health by maintaining normal functions or activating physiological functions of the human body, and is regulated by the Ministry of Food and Drug Safety, but is not limited thereto, and does not exclude any conventional health food from its meaning.
[0131] In addition, the above foods include, but are not limited to, various foods, food additives, beverages (e.g., functional beverages, natural fruit juices and vegetable beverages), gum, tea, vitamin complexes, health functional foods, and other functional foods.
[0132] The above food can be manufactured by a conventional method known in the art. For example, the medical food, nutraceutical food, or health functional food can be formulated into one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations by further including one or more of a carrier, diluent, excipient, and additive in addition to the peptide or its dimer for the purpose of preventing or improving obesity or non-alcoholic fatty liver disease. Specific examples of the carrier, excipient, diluent, and additive are well known in the art, and a person skilled in the art can manufacture the product by combining appropriate ingredients according to the formulation.
[0133] The content of the peptide or its dimer according to the present invention as an effective ingredient in the above-described formulation can be appropriately adjusted depending on the form and purpose of use, the patient's condition, the type and severity of symptoms, etc., and may be 0.001 to 99.9 wt%, preferably 0.01 to 50 wt%, based on the solid weight, but is not limited thereto.
[0134] The dosage of the food of the present invention may vary depending on the patient's age, weight, sex, dosage form, health condition, and disease severity, and may be administered once or several times a day at regular intervals at the discretion of a doctor or pharmacist. For example, the daily dosage may be 10 to 1,000 mg / kg based on the content of the active ingredient. The above dosage is an example of an average case, and the dosage may be higher or lower depending on individual differences. If the daily dosage of the health functional food of the present invention is less than the above dosage, a significant effect may not be obtained, and if it exceeds it, it is not only uneconomical but also goes beyond the range of commercial dosage, so undesirable side effects may occur.
[0135] In the present invention, food can be used interchangeably with feed composition when applied to animals other than humans.
[0136] According to another aspect of the present invention, a feed composition comprising a mitochondrial-specific peptide or a dimer thereof disclosed herein as an active ingredient is provided.
[0137] The feed composition of the present invention can be prepared in any formulation commonly used in the art. For example, the feed composition of the present invention may further include auxiliary ingredients such as amino acids, inorganic salts, vitamins, antibiotics, antimicrobial substances, antioxidants, antifungal enzymes, and other microbial preparations in the form of live bacteria; grains such as ground or crushed wheat, oats, barley, corn, and rice; plant-based protein feeds such as those mainly composed of rapeseed, soybeans, and sunflower; animal-based protein feeds such as blood meal, meat meal, bone meal, and fish meal; dry ingredients composed of sugars and dairy products such as various types of milk powder and whey powder; lipids such as animal fats and vegetable fats optionally liquefied by heating, and the like as main ingredients; and additives such as nutritional supplements, agents for enhancing digestion and absorption, growth promoters, and disease preventive agents.
[0138] The feed composition of the present invention may be in the form of a powder or liquid formulation, and may include an excipient for feed addition (calcium carbonate, malt powder, zeolite, corn powder, or rice bran, etc.).
[0139] When the feed composition of the present invention is provided as a feed additive, it can be supplied alone or mixed into feed for poultry, livestock, companion animals, etc. Since the feed additive of the present invention has the effect of preventing or improving obesity or non-alcoholic fatty liver disease, by continuously consuming it for poultry, livestock, companion animals, etc., metabolic diseases (e.g., obesity, etc.) can be prevented and diseases that have already occurred can be improved.
[0140] In one embodiment, when the mitochondrial-specific peptide or dimer thereof of the present invention is provided as a food composition or feed composition, it can be orally administered to humans and non-human animals.
[0141] Methods of prevention or treatment
[0142] According to another aspect of the present invention, a method for preventing or treating a disease or condition in a subject is provided, comprising administering to the subject a mitochondrial-specific peptide or a dimer thereof disclosed herein, or a composition disclosed herein. The disease or condition refers to the uses and / or effects of the mitochondrial-specific peptide or dimer thereof of the present invention.
[0143] In one embodiment, the peptide of the present invention or a dimer thereof may be administered to a subject in a preventive or therapeutically effective amount. As used herein, the term "preventive or therapeutically effective amount" or "effective amount" refers to the amount of an active ingredient required to prevent or treat obesity or non-alcoholic fatty liver disease in a subject, which is sufficient to prevent or treat the disease at a reasonable benefit / risk ratio applicable to medical treatment, and does not cause side effects. The level of the effective amount may be determined based on factors including the patient's health condition, the type and severity of the disease, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the frequency of administration, the route of administration and excretion rate, the duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. It is important to take all of the above factors into consideration and administer an amount that can achieve the maximum effect with the minimum amount of side effects or without side effects, and this can be easily determined by those skilled in the art. In general, although the scope of the present invention is not limited thereto, the daily dosage may be 0.001 to 100 mg / kg, specifically 0.01 to 10 mg / kg, and more specifically 0.1 to 10 mg / kg. Administration may be once a day or divided into several times, and administration may be performed over a long period of time or over a long period of time by implanting an infusion pump or the like.
[0144] The composition according to the present invention can be administered to a subject via various routes. Any route of administration is conceivable, including oral or parenteral administration. Parenteral administration refers to administration via injection (e.g., bolus injection) or infusion. Parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection, intraarterial injection, intraperitoneal injection, intracerebral injection, intrathecal injection, or intracerebroventricular injection. Administration may also be systemic or local, targeting tissues, organs, etc. associated with a lesion.
[0145] In one embodiment, the mitochondrial-specific peptide or dimer thereof disclosed herein may be administered in combination with another agent effective for the prevention or treatment of obesity or fatty liver disease. The other agent for combination administration may be a substance that exhibits complementary or synergistic activity to achieve the desired effect of the peptide or dimer thereof of the present invention. The peptide or dimer thereof of the present invention and the other agent may be administered simultaneously, sequentially, or in reverse order.
[0146] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention, and the scope of the present invention is not limited to these examples.
[0147] Example
[0148] Manufacturing Example 1. Manufacturing of a mitochondrial-specific peptide
[0149] Manufacturing Example 1.1. Synthesis of Monomeric Peptides
[0150] Peptides were synthesized using a standard 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS) method on an SPS microwave peptide synthesizer (Discover, CEM, USA). Two monomeric peptides were prepared in acetyl-capped or fluorescently labeled forms.
[0151] Specifically, rink amide MBHA resin was deprotected using 20% (v / v) piperidine in N,N-dimethylformamide (DMF), and the Fmoc-protected amino acids were coupled in the presence of N,N-diisopropylethylamine (DIPEA) and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP). The resin was washed several times with DMF and dichloromethane (DCM) with gentle shaking. Deprotection and coupling were repeated until the peptide of the desired sequence was synthesized. After the addition of the last amino acid, the N-terminus of the peptide was acetylated. Acetylation was performed by adding acetic anhydride and 1-hydroxybenzotriazole hydrate (HOBt).
[0152] To synthesize the fluorescently labeled form of the peptide, 5-carboxytetramethylrhodamine (5-TAMRA) was conjugated to the peptide using DMF in the presence of O-(1H-6-chlorobenzotriazole1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), HOBt, and DIPEA. 6-(7-nitrobenzofurazan-4-ylamino)hexanoic acid (C6-NBD) was labeled using PyBOP and DIPEA in DMF.
[0153] The peptide synthesized on the resin was cleaved using a cleavage mixture [trifluoroacetic acid (TFA) / 1,2-ethanedithiol (EDT) / distilled water / triisopropylsilane (TIS) = 94:2.5 / 2.5 / 1, v / v]. For precipitation, a 1:1 (v / v) mixture of n-hexane and diethyl ether was added to the cleaved peptide. The precipitated peptide was centrifuged at 5,000 rpm for 15 min, and the peptide pellet was dissolved in DMSO.
[0154] Purification of the peptide was performed using high-performance liquid chromatography (HPLC). The mobile phase consisted of water containing 0.1% (v / v) TFA (buffer A) and acetonitrile (ACN) containing 0.1% (v / v) TFA (buffer B), and the stationary phase was a Zorbax C18 column (3.5 μm, 4.6 mm × 150 mm). The purified peptide was lyophilized and dissolved in an appropriate solvent. The molecular weight of the peptide was determined using a MALDI-TOF mass spectrometer (Bruker, USA).
[0155] After synthesizing acetyl-capped monomeric peptides (CMP3001m to CMP3015m) and N-terminally fluorescently labeled monomeric peptides with TAMRA (FL-CMP3001m to FL-CMP3015m), monomeric peptides with excellent ROS production inhibitory effects (CMP3029m to CMP3032m) were further synthesized by combining preferred hydrophobic amino acids at positions 1, 4, 5, and 8 of the hydrophobic moiety.
[0156] Among these, the purity, calculated mass and observed mass of the acetyl-capped forms (see Table 2) and the N-terminally fluorescently labeled forms with TAMRA (see Table 3) of the monomeric peptides (CMP3013m and CMP3029m) used in the experiment are shown in Tables 2 and 3 below.
[0157]
[0158]
[0159] Manufacturing Example 1.2. Synthesis of a dimeric peptide
[0160] To convert the prepared monomeric peptides into dimer bundles, air oxidation was used to form disulfide bonds between the two monomeric peptides. Specifically, lyophilized, non-fluorescently labeled monomeric peptides were oxidized at a concentration of 5–10 mg / ml in 0.1 M ammonium bicarbonate (0.1 M NH4HCO3) buffer under air while stirring. In some cases, ACN was added up to 40% (v / v) to increase the solubility of the peptides. Synthesis of fluorescently labeled dimer bundle peptides was performed by mixing non-fluorescently labeled monomeric peptides and TAMRA-labeled monomeric peptides in a 1:1 ratio and dimerization. The prepared peptide dimers were purified by HPLC and lyophilized.
[0161] The amino acid sequence and purity analysis, MALDI-TOF mass spectrometry (calculated mass and observed mass) results of the dimeric peptide CMP3013 or CMP3029 purified by HPLC and the fluorescently labeled dimeric bundle peptide FL-CMP3013 or FL-CMP3029 are shown in Tables 4 and 5 below (in the above tables, the line between two cysteines represents a disulfide bond).
[0162]
[0163]
[0164] Manufacturing Example 1.3. Confirmation of the sequence directionality of each monomer in a dimeric peptide.
[0165] To determine whether each unit in the dimeric peptide binds in an antiparallel direction to each other, an experiment was performed in which two cysteines (C) contained in the monomer were treated with different protecting groups, Trt (triphenyl methyl) and Acm (acetamidomethyl). Since the Trt protecting group is cleaved from the thiol under acidic conditions, the cysteine remains in the thiol form when treated with a cleavage mixture containing TFA. In contrast, the Acm protecting group is removed only under strong oxidizing conditions, so the protecting group remains attached to the thiol even when treated with a cleavage mixture containing TFA.
[0166] First, two monomer peptides each having one cysteine-Trt and one cysteine-Acm at two different cysteine positions (X2, X9) in the monomer peptide were prepared by a solid-phase peptide synthesis method. Next, a disulfide bond was formed between the two different monomer peptides under air oxidation conditions, and the dimeric peptide having only one disulfide bond was purified by HPLC. Afterwards, the dimeric peptide having only one disulfide bond was dissolved in triple-distilled water containing 10% acetic acid, and a methanol solution containing iodine was added dropwise, thereby reacting for 50 minutes under strong oxidizing conditions to remove the Acm protecting group and form a new disulfide bond. Additionally, dimeric peptides were synthesized by air oxidation reaction, and the retention times of the antiparallel dimeric peptides synthesized using the protecting group above were measured on HPLC (data not shown).
[0167] After confirming that the monomer peak disappeared and a new peak was formed in HPLC chromatography, the mass of the peak was analyzed by MALDI-TOF MS, and it was confirmed that a dimer with a mass approximately twice that of the monomer was formed. Through HPLC chromatograms of the dimeric peptide and the antiparallel dimeric peptide by air oxidation and the chromatograms for the individual reaction products (antiparallel dimer), it was confirmed that the dimeric bundle peptide formed by air oxidation had an antiparallel structure.
[0168] Example 1. Efficacy of mitochondrial-specific peptides
[0169] Mitochondrial-specific peptides (e.g., CMP3013, CMP3029) produced according to the method described in Manufacturing Example 1 have been confirmed in previous studies to have excellent mitochondrial targeting ability (particularly, targeting damaged mitochondria), and excellent abilities to inhibit mitochondrial ROS production, promote ATP production, and restore membrane potential. In addition, the peptides disclosed in the present invention were confirmed to penetrate into cells by endocytosis, escape from endosomes, preferentially translocate to damaged mitochondria, and specifically bind to multiple cardiolipins in the mitochondrial inner membrane to restore the structure of cristae, thereby regenerating the curvature of the mitochondrial inner membrane. In this way, the peptides disclosed in the present invention specifically and strongly bind to cardiolipin or pathogenically remodeled cardiolipin-containing membranes, thereby gathering functional proteins of the mitochondria, thereby correcting mitochondrial dysfunction.
[0170] For mitochondrial-specific peptides, see Korean Patent Application No. 10-2022-0131798, the disclosure of which is hereby incorporated herein in its entirety.
[0171] Example 2. Inhibition of fat accumulation through mitochondrial recovery in hepatocytes (HepG2)
[0172] Example 2.1. Confirmation of the effect of inhibiting ROS production and restoring membrane potential.
[0173] Confirmation of ROS generation inhibition effect
[0174] To confirm the recovery effect of mitochondria-specific peptides on ROS production inhibition, human hepatocytes were treated with hydrogen peroxide (H2O2) to mimic the conditions of mitochondrial dysfunction caused by non-alcoholic fatty liver disease. First, 1.5 × 10 4HepG2 cells were cultured in 96-well black plates for 24 h. After 24 h, the cells were treated with CMP3013 at three different concentrations (10 nM, 30 nM, or 100 nM), cultured for 3 h, and stained with H2DCFDA (25 μM, 30 min). After washing twice with HBSS, the cells were treated with 0.5 mM H2O2 for 30 min to induce ROS production. The DCF signal of each well was obtained using a microplate reader (TECAN) at 37°C (Ex / Em = 485 / 535 nm). As a result, all concentrations of CMP3013 treatment groups, including the lowest concentration of 10 nM, showed superior ROS production inhibition effects compared to the H2O2 treatment group (Fig. 2a).
[0175] Confirmation of the effect of restoring mitochondrial membrane potential
[0176] To confirm the effect of mitochondria-specific peptides on restoring mitochondrial membrane potential, HepG2 cells were treated with CMP3013 in the same manner as described above, and then mitochondrial membrane potential damage was induced by treating with 1 mM H2O2 in a 37℃ incubator for 1 hour. After 1 hour, the cells were washed twice with HBSS and stained with 600 nM tetramethylrhodamine, ethyl ester (TMRE) in a 37℃ incubator for 20 minutes. The buffer was then replaced with PBS (containing 0.2% BSA). The fluorescence intensity of TMRE in each well was obtained using a microplate reader (TECAN) (Ex / Em = 525 / 575 nm). As a result, it was confirmed that the mitochondrial membrane potential damage caused by H2O2 was recovered in all concentrations of CMP3013 treatment groups, and the value was statistically significant (Fig. 2b).
[0177] Example 2.2. Confirmation of the effect of suppressing fat accumulation
[0178] Oleic acid, which is actively used in research on non-alcoholic fatty liver disease, was used to induce fat accumulation in hepatocytes, and the inhibitory effect of mitochondrial-specific peptides on fat accumulation was confirmed. Specifically, 8.5 × 10 4 HepG2 cells were seeded in 24-well plates and cultured in a 37℃ incubator for 24 h, and then treated with 500 μM oleic acid and three concentrations (10 nM, 30 nM, or 100 nM) of CMP3013, respectively, and cultured in a 37℃ incubator for 24 or 48 h. After 24 or 48 h, the accumulated fat in the hepatocytes was stained using an Oil Red O stain kit (abcam, ab150678) and observed under an optical microscope (Fig. 3a). All procedures were performed according to the manufacturer's instructions. As a result, it was confirmed that the fat accumulation phenomenon that was clearly observed in the oleic acid treatment group was significantly reduced in the CMP3013 treatment group, and the low-concentration CMP3013 treatment group (10 nM) also showed an inhibitory effect on fat accumulation.
[0179] Next, each well was treated with 100% isopropanol to dissolve the fat, and the absorbance was measured at a wavelength of 500 nm using a microplate reader (TECAN) to determine the remaining fat content. As a result, the CMP3013 treatment group showed a concentration-dependent fat accumulation inhibition effect (Fig. 3b). In addition, the CMP3013 treatment group showed a time-dependent fat accumulation inhibition effect. That is, the fat accumulation inhibition effect was superior in the group treated with CMP3013 for 48 hours than in the group treated for 24 hours (Fig. 3c).
[0180] Meanwhile, to exclude the effect of oleic acid cytotoxicity, a cytotoxicity test (WST-1) was conducted. Specifically, 1.5 × 10 4HepG2 cells were seeded in 96-well plates and cultured in a 37°C incubator for 24 h. After 24 h, oleic acid was treated to each well at concentrations of 0.0625, 0.125, 0.5, 1, 2, and 4 mM, and the wells were cultured in a 37°C incubator for another 24 h. After 24 h, the culture medium was replaced with fresh medium, and 10 μL of EZ-Cytox (DoGEN, Korea) was treated per well, cultured for 30 min, and the absorbance was measured at 450 nm. As a result, cytotoxicity was observed only at concentrations higher than 2 mM, and it was confirmed that 20% of the cultured cells were killed at 2 mM (Fig. 3d). Therefore, it was confirmed that 500 μM oleic acid had no effect on the lipid accumulation-reducing effect of CMP3013.
[0181] Example 2.3. Comparison of the Fat Accumulation Inhibitory Effects of Exendin-4 and CMP3013
[0182] As illustrated in Fig. 4a, Exendin-4 (Ex-4), a peptide agonist of the glucagon-like peptide (GLP) receptor (GLR-1R), is known to improve hepatic fat accumulation by promoting lipolysis. Using Exendin-4 as a comparative group to CMP3013, the inhibitory effects of Exendin-4 (200 nM) or CMP3013 (10 nM, 30 nM, or 100 nM) on fat accumulation were compared in HepG2 hepatocytes induced with oleic acid in the same manner as described in Example 2.2.
[0183] As a result, both Exendin-4 and CMP3013 showed a fat accumulation inhibitory effect in HepG2 hepatocytes induced with oleic acid, and the group treated with 30 nM CMP3013 showed a better fat accumulation inhibitory effect than the group treated with 200 nM Exendin-4, and the value was statistically significant (Fig. 4b).
[0184] Example 3. Suppression of obesity in a high-fat diet animal model
[0185] Example 3.1. Checking body weight and feed intake
[0186] As shown in Fig. 5, 8-week-old C57BL / 6 mice were fed a 60% high-fat diet (approximately 20 g / week) for 4 weeks to establish an obesity model with an average body weight of approximately 35 g (weeks 0 to 4). CMP3013 was injected intraperitoneally at a dose of 1 mg / kg every other day for 5 weeks into the mice induced to be obese through the high-fat diet (HFD) (weeks 4 to 9). The control group was injected with the same amount of saline (vehicle). To maximize obesity in the mice, the high-fat diet (approximately 20 g / week) was maintained during the CMP3013 administration period. The body weight and feed intake of the mice were measured at weekly intervals from the start of CMP3013 administration. The change in body weight was calculated by the following formula: ((last measured weight - initial weight) / initial weight) * 100 (%). At the end of the 9th week of the experiment, the CMP3013-administered group showed approximately 30% reduction in body weight change compared to the control group (Figures 6a to 6c). Feed intake was calculated as the remaining feed amount (g) compared to the previous week, and no difference was observed between the groups each week (Figure 6d). This indicates that the obesity-improving effect of CMP3013 was independent of feed intake. In addition, when the blood glucose (mg / dL) levels were measured after fasting for 12 hours in the 9th week of administration, no significant difference was observed between the control and CMP3013-administered groups (Figure 6e).
[0187] Example 3.2. Morphological observation of metabolic tissues
[0188] At the end of the 9th week of the experiment, the mice were sacrificed, and tissues related to metabolism (liver, visceral fat (iWAT), subcutaneous fat (eWAT), and brown adipose tissue (BAT)) were collected, and the morphology of the tissues was observed and the weight was measured (Fig. 7a and Fig. 7b). The CMP3013-administered group showed an overall decrease in external size compared to the control group (Fig. 7a), and the weight of the liver, visceral fat, and brown adipose tissue decreased by approximately 0.2 g, 0.3 g, and 50 mg, respectively (Fig. 7b). In particular, the liver of the control group showed an abnormal appearance with pale and edematous appearance, whereas the liver of the CMP3013-administered group showed a smooth surface with a light pink color.
[0189] Example 3.3. Confirmation of the therapeutic effect on fatty liver and NASH through histological staining.
[0190] In Example 3.2, since the morphology and weight of the liver showed a significant difference between the CMP3013 administration group and the control group (Fig. 7a and Fig. 7b), H&E staining was performed for histological observation. The livers of mice sacrificed in the 9th week of the experiment were collected, fixed in 4% neutral buffered formalin for one day, dehydrated, and then paraffin was infiltrated into the tissue using a tissue processor (Leica TP1020). Paraffin blocks containing the tissue were prepared in a form easy for sectioning, and the sections were thinly sliced to a thickness of 4.0 ㎛ and mounted on slide glasses for tissue staining to complete the tissue specimen. The tissue specimens that went through the deparaffinization and dehydration process were stained in a hematoxylin solution (nuclear stain) for approximately 2 minutes and in an eosin solution (cytoplasmic stain) for approximately 30 seconds to stain the nucleus and cytoplasm. After the staining was completed, the tissues were sealed and observed under a microscope, and photographs were taken from each of the four animals at a magnification of 100x (Fig. 8).
[0191] In the livers of mice induced to be obese through a high-fat diet, cells with advanced steatosis or ballooning, or inflammatory lesions were observed (Figs. 9a to 9c). These three characteristics indicate that the disease progressed from a fatty liver state to NASH accompanied by inflammation. Interestingly, it was confirmed that NASH indicators were significantly reduced in the livers of mice administered CMP3013 compared to the control group. Specifically, the proportion of cells with advanced ballooning was significantly reduced from 50% to 10% by administration of CMP3013 (Fig. 9a), and the ballooning score, calculated as the ballooning score, also significantly decreased from 75% to 30% (Fig. 9b). It was confirmed that the steatosis score decreased from 75% to approximately 30% (Fig. 9c). NASH can be determined by checking the NAFLD activity score (NAS), referring to the classification method described in Experimental Example 1.
[0192] Furthermore, while inflammatory response factors were found in hepatocytes in the control group, these lesions virtually disappeared in the CMP3013-treated group (Fig. 9d). This suggests that mitochondrial-specific peptides (e.g., CMP3013) could be used as effective treatments for NASH caused by obesity.
[0193] Example 4. Inhibition of inflammatory cytokine secretion and inflammatory macrophage (M1) differentiation
[0194] In liver diseases, including non-alcoholic fatty liver disease, it is generally known that endotoxins such as lipopolysaccharide (LPS) infiltrate through a weakened liver barrier. Ingested LPS travels to the liver via the bloodstream, promoting macrophage differentiation into proinflammatory macrophages (M1) and the secretion of inflammatory cytokines, along with increased ROS production. Furthermore, the increase in M1 and cytokines further exacerbates liver inflammation.
[0195] To confirm the inhibitory effect of CMP3029 on the secretion of inflammatory cytokines and differentiation into inflammatory macrophages (M1), the following procedures were performed: 1) isolation of bone marrow cells, 2) induction of differentiation into bone marrow-derived macrophages (BMDMs), 3) analysis of cells and cell culture media, and 4) cytotoxicity evaluation. RPMI supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics and antifungals (penicillin, streptomycin, and Fungizone) was used as the basic medium, and MCSF (30 ng / ml) was added for differentiation into macrophages. A schematic diagram of the isolation of bone marrow cells, differentiation into bone marrow-derived macrophages, and treatment with LPS and CMP3029 is shown in Figure 10.
[0196] 1) Isolation of bone marrow cells
[0197] Male C57BL / 6 mice, aged 7 to 10 weeks, were sacrificed and calf and thigh bones were obtained. Cells were extracted by injecting PBS into the calf and thigh bones using a 26-gauge syringe. Additionally, red blood cells were removed using RBC lysis buffer, and bone marrow cells were finally obtained.
[0198] 2) Induction of differentiation into bone marrow-derived macrophages
[0199] Bone marrow cells were centrifuged, resuspended in RPMI medium, and cultured for 24 hours in a 37°C incubator. After obtaining the cells in the supernatant, they were cultured for 4 days in RPMI medium supplemented with MCSF (30 ng / ml). After that, the cells attached to the dish were harvested and seeded in a 24-well cell culture plate at a density of 2.5 × 10 per well. 5 It was seeded and cultured with dog cells.
[0200] 3) Cell and cell culture analysis
[0201] Bone marrow-derived macrophages were treated with LPS (100 ng / ml) and CMP3029 (500 nM or 1 μM) and cultured for 24 hours. The culture supernatant was collected, and the concentrations of IL-6, TNF-α, and IL-10 were measured by ELISA. IL-1β was measured after secondary stimulation with nigericin (10 μM) for 30 minutes. Meanwhile, the cells were stained with a fixable viability dye at 4°C for 30 minutes, and then stained with F4 / 80, CD86, MHCⅡ, and CD38 antibodies for 30 minutes at 4°C. After staining, the cells were analyzed using a flow cytometer (BD Biosciences, BD AccuriTM C6 Flow Cytometer).
[0202] As a result, it was confirmed that the secretion of inflammatory cytokines (IL-6, TNF-α, and IL-10) increased by LPS treatment was significantly reduced by CMP3029 treatment (Fig. 11a). In addition, IL-1β, an inflammasome indicator increased by LPS and nigericin, was also reduced by CMP3029 treatment (Fig. 11b). Meanwhile, in the case of cells measured through flow cytometry, it was confirmed that M1 markers (F4 / 80, CD86, MHCⅡ, and CD38) increased by LPS treatment, and it was confirmed that differentiation into M1 was inhibited as the expression levels of CD86, MHCⅡ, and CD38 decreased by CMP3029 treatment (Figs. 12a to 12d).
[0203] 4) Cytotoxicity evaluation
[0204] To evaluate the cytotoxicity of CMP3029 on bone marrow-derived macrophages, differentiation of bone marrow-derived macrophages was induced through the above methods 1) and 2), and then 2 × 10 per well 4 Cells were cultured in 96-well plates. Each well was treated with CMP3029 at concentrations of 0, 100, 500, or 1,000 nM and cultured for 24 h. CCK8 (Cell Counting Kit 8) (Manufacturer: Dong-In LS, CAT. NO: CCK-100) was then treated for 4 h according to the manufacturer's protocol, and the absorbance at OD450 nm was determined. As a result, it was confirmed that CMP3029 did not affect cell viability even at a concentration of 1 μM, confirming the absence of toxicity in the 1 μM concentration range (Fig. 13).
[0205] conclusion
[0206] In NAFLD, the intrahepatic environment influences macrophage activation, promoting differentiation into inflammatory macrophages (M1) and the secretion of inflammatory cytokines through increased endogenous ROS in macrophages. Additionally, a high-fat diet (e.g., HFD) weakens and loosens the intestinal barrier, increasing the influx of endotoxins (e.g., LPS). Once in the bloodstream, LPS travels to the liver and stimulates hepatocytes or macrophages, accelerating the progression of NASH. In NASH, further damage to hepatocytes and a weakened intestinal barrier further increases the influx of endotoxins, which can further promote the activation of inflammatory macrophages and exacerbate the resulting inflammation.
[0207] In mast cells, cardiolipin synthase (CLS), which supports the inner mitochondrial membrane, is lacking, resulting in a loose inner mitochondrial membrane. This release of oxidized and damaged cardiolipin is believed to form inflammasomes and release various inflammatory cytokines. Previous studies have demonstrated that the mitochondrial-specific peptides of the present invention (e.g., CMP3013, CMP3029, etc.) specifically bind to cardiolipin, inducing structural stabilization and thereby normalizing mitochondria. Mitochondrial restoration can suppress ROS production and endotoxin influx, thereby inhibiting the differentiation of inflammatory macrophages and the secretion of inflammatory cytokines. Therefore, the mitochondrial-specific peptides of the present invention are expected to be useful as therapeutic agents for NAFLD or NASH.
[0208] Experimental Example 1. Confirmation of NAFLD Activity Score (NAS)
[0209] The NAFLD Activity Score (NAS) can be useful in identifying patients with NASH and is based on the criteria in the table below. The NAS is expressed as the sum of individual scores for steatosis (0–3), hepatocyte ballooning (0–2), and lobular inflammation (0–3).
[0210] Components of the NAFLD Activity Score (NAS) Component Score Description Steatosis 0 <5% 15-33% 2 > 33-66% 3 > 66% Lobular Inflammation 0 No foci 1 < 2 foci / 200x 22-4 foci / 200x 3 > 4 foci / 200x Hepatocyte Ballooning 0 None 1 Few ballooned cells 2 Many ballooned cells / marked ballooning
[0211] The steatosis score indicates the amount of surface area associated with steatosis, as assessed on low- and medium-power examinations. Lobular inflammation refers to inflammation excluding eosinophilic and portal inflammation. Hepatocyte ballooning refers to a type of cell death visually characterized by enlargement and localization of the cell center, nucleus, or adjacent portions. A higher NAS score indicates progression to / is progressing to NASH.
[0212] Experimental Example 2. Statistical Analysis
[0213] All unpaired Student's t-tests were performed using GraphPad Prism software. Data represent means, and error bars represent standard deviations. Statistical significance was assessed by a p value less than 0.05 (ns, p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001).
Claims
1. A pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver disease, comprising as an active ingredient a peptide or a dimer thereof comprising a unit represented by the following formula 1: <Formula 1> X1X2X3X4X5X6X7X8X9X 10 In the above equation 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, X3, X6, X7 and X 10 are each independently hydrophilic amino acids, X2 and X9 are each independently amino acids that form a bond so that each unit can be linked to each other at at least one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
2. In paragraph 1, The above non-alcoholic fatty liver disease is selected from the group consisting of hyperlipidemia, simple hepatic steatosis, metabolic liver disease, obesity-related fatty liver disease, diabetic fatty liver disease, liver fibrosis, liver failure, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Pharmaceutical composition.
3. In paragraph 1, A pharmaceutical composition wherein the peptide or dimer thereof exhibits at least one of the following characteristics: (ⅰ) Inhibition of mitochondrial ROS (reactive oxygen species) production, (ⅱ) Restoration of mitochondrial membrane potential; (ⅲ) weight loss, (ⅳ) Weight loss or shape change of metabolic tissues; (ⅴ) Improvement of NASH indicators; (ⅵ) Inhibition of differentiation into inflammatory macrophages, and (ⅶ) Inhibition of expression or reduction of activity of inflammatory cytokines.
4. In paragraph 3, The weight loss or morphological change of the above metabolic related tissues includes weight loss or restoration to normal tissue morphology in at least one tissue selected from the group consisting of liver, visceral fat, subcutaneous fat and brown fat. Pharmaceutical composition.
5. In paragraph 3, The above NASH indicators include cells with advanced steatosis or ballooning or inflammatory lesions. Pharmaceutical composition.
6. In paragraph 3, The above inflammatory macrophages express M1 macrophage markers selected from the group consisting of F4 / 80, CD86, MHCⅡ and CD38. Pharmaceutical composition.
7. In paragraph 3, The above inflammatory cytokine is selected from the group consisting of IL-6, TNF-α, IL-10 and IL-1β. Pharmaceutical composition.
8. In paragraph 1, The above X1, X4, X5 and X8 are each independently leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y), valine (V), norvaline (norV), tryptophan (W), pentylglycine (pg), neopentylglycine (Npg), alanine (A) or cyclohexylalanine (Cha). Pharmaceutical composition.
9. In paragraph 1, The above X1, X4, X5 and X8 are each independently leucine (L), isoleucine (I), phenylalanine (F), tyrosine (Y) or cyclohexylalanine (Cha). Pharmaceutical composition.
10. In paragraph 1, At least one of the above X1, X4, X5 and X8 is each independently cyclohexylalanine (Cha). Pharmaceutical composition.
11. In paragraph 1, The above X3, X6, X7 and X 10 are each independently arginine (R), lysine (K), homoarginine (hR), norarginine (norR), histidine (H), ornithine (O), diaminobutanoic acid (Dab), or diaminopropanoic acid (Dap). Pharmaceutical composition.
12. In paragraph 1, The above X3, X6, X7 and X 10 are each independently arginine (R), lysine (K), homoarginine (hR), norarginine (norR), or histidine (H). Pharmaceutical composition.
13. In paragraph 1, The above X2 and X9 are each independently cysteine (C), homocysteine (Hcy), penicillamine (Pen), selenocysteine (U), or leucine (L), provided that X2 and X9 are not both leucine (L). Pharmaceutical composition.
14. In paragraph 1, The above dimer is a peptide represented by formula 1 that is connected in an anti-parallel direction to each other. Pharmaceutical composition.
15. In paragraph 1, The peptide represented by the above formula 1 is composed of any one of the amino acid sequences of SEQ ID NO. 1 to SEQ ID NO.
19. Pharmaceutical composition.
16. In paragraph 1, The above peptide or its dimer has the activity of binding to mitochondria. Pharmaceutical composition.
17. A food composition for controlling obesity or non-alcoholic fatty liver disease, comprising a peptide or a dimer thereof containing a unit represented by the following formula 1 as an active ingredient: <Formula 1> X1X2X3X4X5X6X7X8X9X 10 In the above equation 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, X3, X6, X7 and X 10 are each independently hydrophilic amino acids, X2 and X9 are each independently amino acids that form a bond so that each unit can be linked to each other at at least one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
18. A method for preventing or treating obesity or non-alcoholic fatty liver disease, comprising administering to a subject in need thereof a peptide or a dimer thereof comprising a unit represented by the following formula 1: <Formula 1> X1X2X3X4X5X6X7X8X9X 10 In the above equation 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, X3, X6, X7 and X 10 are each independently hydrophilic amino acids, X2 and X9 are each independently amino acids that form a bond so that each unit can be linked to each other at at least one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
19. A method for reducing the weight of a subject or suppressing weight gain of a subject, comprising administering to a subject in need thereof a peptide or a dimer thereof comprising a unit represented by the following formula 1: <Formula 1> X1X2X3X4X5X6X7X8X9X 10 In the above equation 1, X1, X4, X5 and X8 are each independently hydrophobic amino acids, X3, X6, X7 and X 10 are each independently hydrophilic amino acids, X2 and X9 are each independently amino acids that form a bond so that each unit can be linked to each other at at least one position among X2 and X9 to form a dimeric peptide, X1 is the N-terminal and X 10 is the C-terminal.
Citation Information
Patent Citations
Pharmaceutical composition for the prevention or treatment of fat liver comprising GDF15 protein or polynucleotide encoding GDF15 as an effective ingredient
KR101727506B1
Cosmetic composition effective for skin improvement containing palmitoyl tripeptide compound
KR1020210150839A
Premium customer service method of technology auction platform application
KR1020230045142A
Apparatus and method for providing medical device suggestion service based on internal and external environmental information
KR102478231B1
Mitochondria-targeting protein and use thereof
WO2021145743A1
